19 May 2013
Keywords: eli, lilly, file, nda, arxxant, dr, sees
Article | 08 August 2005
Indianapolis, USA-headquartered drug major Eli Lilly has completed a Phase III trial of its investigational drug Arxxant (ruboxistaurin
mesylate), which ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 August 2005
15 August 2005
17 May 2013
© 2013 thepharmaletter.com